Cannot smell right ever since he got the Moderna shots, in fact, he can hardly smell at all/loss of smell; Loss of taste; Metallic taste/metallic saliva with all foods; Had COVID-19 after the first dose; This spontaneous case was reported by a patient and describes the occurrence of ANOSMIA (Cannot smell right ever since he got the Moderna shots, in fact, he can hardly smell at all/loss of smell), AGEUSIA (Loss of taste), DYSGEUSIA (Metallic taste/metallic saliva with all foods) and COVID-19 (Had COVID-19 after the first dose) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A211A) for COVID-19 vaccination.     The patient had no other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  The patient's past medical history included COVID-19 (Mild COVID with runny nose and mild symptoms.) in 2020. Concurrent medical conditions included Grass allergy, Grass allergy, Type 2 diabetes mellitus, Sleep apnea and Blood pressure high. Concomitant products included METFORMIN, OMEPRAZOLE, METOPROLOL, ATORVASTATIN, GLIPIZIDE and HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (LOSARTAN/HYDROCHLOORTHIAZIDE) for an unknown indication.    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced ANOSMIA (Cannot smell right ever since he got the Moderna shots, in fact, he can hardly smell at all/loss of smell), AGEUSIA (Loss of taste), DYSGEUSIA (Metallic taste/metallic saliva with all foods) and COVID-19 (Had COVID-19 after the first dose). At the time of the report, ANOSMIA (Cannot smell right ever since he got the Moderna shots, in fact, he can hardly smell at all/loss of smell), AGEUSIA (Loss of taste) and DYSGEUSIA (Metallic taste/metallic saliva with all foods) had not resolved and COVID-19 (Had COVID-19 after the first dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2020, SARS-CoV-2 test: Positive.     mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       According to the patient none of the food he ate had good taste anymore; that was 70 % of the food he ate. For example, bacon, peanut butter, salad dressing and meat product. The only thing he could taste was chocolate, sugary stuff like pie. For some reason the loss of taste did not seem to affect sugary product. Patient reported he checked with his family physician about the atorvastatin which he thought could have caused bitterness in mouth. Patient reported the physician switched his medication and that did not do anything to the bitterness, which he is still experiencing. The metallic taste never went away. The patient could not smell right ever since he got the Moderna vaccine, in fact, he could hardly smell at all. The patient health care professional was aware of the side effects. The patient had COVID-19 after the first dose.  Company comment: This is a spontaneous case concerning a 69-year-old male patient, with medical history of COVID-19 and concurrent medical condition of Type 2 diabetes mellitus, who  experienced non serious events of anosmia (AESI), dysgeusia, ageusia (AESI) and COVID-19 after receiving first dose of mRNA-1273 vaccine. Onset date of the events was not provided, latency cannot be assessed. According to the report, after vaccination patient experienced loss of smell, loss of taste, bitterness on his mouth and metallic taste. For some reason the loss of taste did not seem to affect sugary product. His physician switched his medication, as it was thought that atorvastatin could have caused bitterness in mouth, but symptom persisted. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Medical history of COVID-19 remains a confounding factor for ageusia and anosmia. Type 2 diabetes mellitus and concomitant products Metformin and Losartan could be contributory factors for dysgeusia. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2021-290650, MOD-2022-667034, MOD-2022-667078 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 31-Oct-2022: Live follow-up information included patient's medical history, vaccination date and vaccine batch lot number and indication updated, event onset date, event outcome updated to not recovered and event description updated in narrative supplement.; Sender's Comments: This is a spontaneous case concerning a 69-year-old male patient, with medical history of COVID-19 and concurrent medical condition of Type 2 diabetes mellitus, who  experienced non serious events of anosmia (AESI), dysgeusia, ageusia (AESI) and COVID-19 after receiving first dose of mRNA-1273 vaccine. Onset date of the events was not provided, latency cannot be assessed. According to the report, after vaccination patient experienced loss of smell, loss of taste, bitterness on his mouth and metallic taste. For some reason the loss of taste did not seem to affect sugary product. His physician switched his medication, as it was thought that atorvastatin could have caused bitterness in mouth, but symptom persisted. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Medical history of COVID-19 remains a confounding factor for ageusia and anosmia. Type 2 diabetes mellitus and concomitant products Metformin and Losartan could be contributory factors for dysgeusia. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.